$Alterity Therapeutics(ATHE.US)$Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review Benzinga· 2 mins ago Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended t...
$Alterity Therapeutics(ATHE.US)$ NEWS Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial As Planned After Third Review
Unlocking Hope for Friedreich's Ataxia: The Promising Path of ATH434. The relentless pursuit of medical innovation, certain milestones signal not just progress but a beacon of hope for those ensnared by conditions with limited treatment options. Recently, Alterity Therapeutics has illuminated one such beacon for individuals battling Friedreich's Ataxia (FA), a rare and debilitating neurodegenerative disease. The spotli...
$Alterity Therapeutics(ATHE.US)$Alterity Therapeutics Shares Halted; Co Requested That Its Securities Be Placed Into An Immediate Trading Halt Pending An Announcement In Relation To A Capital Raise Benzinga· 2 mins ago
Trytosaveabit楼主Jaguar8:
Could! But I can’t ever remember having a halt for that? Thinking partnership or something along those lines? Just similar to how I’m thinking on AHI? But I could be way wrong? Hehehe
$Alterity Therapeutics(ATHE.US)$Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review Benzinga· just
Alterity Therapeutics股票讨论区
Benzinga· 2 mins ago
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended t...
NEWS
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial As Planned After Third Review
The relentless pursuit of medical innovation, certain milestones signal not just progress but a beacon of hope for those ensnared by conditions with limited treatment options. Recently, Alterity Therapeutics has illuminated one such beacon for individuals battling Friedreich's Ataxia (FA), a rare and debilitating neurodegenerative disease. The spotli...
Benzinga· 2 mins ago
Benzinga· just
暂无评论